Mumbai-based Glenmark Pharmaceuticals has launched in India the first triple-drug fixed-dose combination (FDC) of the widely used Teneligliptin with Dapagliflozin and Metformin.

This FDC has been launched under the brand name Zita® DM, and it contains the DPP4 inhibitor, Teneligliptin (20mg), the SGLT2 inhibitor, Dapagliflozin, (10mg), and Metformin SR (500mg/1000mg) in a fixed dose. It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes.

On the occasion of the launch, Alok Malik, President & Business Head ‐ India Formulations, Glenmark Pharma stated, “India has the second‐largest diabetic population in the world and Type 2 diabetic patients here often face issues of uncontrolled Hemoglobin A1C (HbA1Ci ), beta cell dysfunction, which impairs insulin secretion, along with other co‐morbidities like weight gain. Diabetes management, hence, becomes difficult for these patients and a challenge for healthcare providers."

Glenmark’s Zita® portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually, in India. With the launch of Zita® DM, Zita® the most comprehensive gliptin range now holds promise of helping Type 2 diabetic patients at every stage of their treatment.

According to IQVIA sales data for the 12-month period ending August 2023 (MAT August 2023), the market for oral anti-diabetic drugs in India is estimated to be Rs 12,522 crore, with an annual growth of 6.5% against the corresponding period last year (MAT August 2022).